33 results found | searching for "pipeline"

2 3 4 Next Last 
  • xarabwkz
  • jameshebrew
  • The human microbiome market is anticipated to grow at a CAGR of 24% till 2035, claims Roots Analysis With the increasing concept of precision medicine, several scientists have demonstrated interest in the therapeutic manipulation of human microbiome (commonly gut bacteria) for the treatment of a wide range of disease indications. Roots Analysis has announced the addition of “The Human Microbiome Market, (4th Edition) 2022-2035” report to its list of offerings. The microbiome-based therapies pipeline features six drugs in phase III clinical development, over 200 candidates in other clinical and preclinical stages of development along with more than 60 diagnostics and screening / profiling tests that are commercialized for the detection of various diseases. However, the current microbiome market is driven by the fecal microbiota therapies approved by the FDA, particularly for the recurrent CDI and the commercialized diagnostic tests available to the patients. The human microbiome remained a largely unexplored area until 2007 when the Human Microbiome Project (HMP) was initiated. Given the role of microbiota in disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, thereby, defining a new frontier in the field of medicine. Key Market Insights Over 230 drug candidates are currently being developed by more than 70 drug developers Nearly 30% of the pipeline drugs are in clinical phase of development, while more than 150 drugs are in preclinical and discovery stages. Clinical stage drugs are primarily being developed for infectious diseases and digestive disorders, while candidates in preclinical and discovery stages are focused on oncological disorders. More than 75 diagnostics and screening / profiling test are available / under development Of these, around 80% of the tests are available in the market, while rest are under development. More than 40 companies are engaged in providing these tests; these are primarily based in North America (45%) and Europe (39%). It is worth highlighting that majority (68%) of the players are small companies. FMTs are the only commercially available microbiome therapies approved by the FDA These therapies are primarily used for the treatment of recurrent Clostridium difficile infection (rCDIs). It is worth mentioning that more than 400 trials have been registered for evaluating these therapies for a wide range of indications. Partnership activity in this domain has increased at a CAGR of 26%, between 2017 and 2021 Maximum number of partnerships were established in 2021, indicating a recent rise in the interest of players engaged in this domain. It is worth highlighting that majority of the deals were R&D agreements, representing over 35% of the total number of partnerships signed in the given time period. More than USD 1 billion has been invested by both private and public investors, since 2017 Of the total amount invested, over USD 563 million was raised through venture capital financing, representing over 56% of the overall funding activity in this domain. Further, 36 instances of grants / awards were also reported, wherein players collectively raised more than USD 137 million. Outsourcing has become an integral part of the microbiome and live biotherapeutics development process Presently, over 25 service providers claim to offer a multitude of contract manufacturing services for microbiome and live biotherapeutic products. It is worth noting that close to 10 firms were established post 2010 and around 45% of the players are located in Europe. Microbiome therapeutics are anticipated to capture more than 60% share of total microbiome market by 2035 As late-stage therapeutics will get approved by the FDA in the foreseen future, the microbiome therapeutics market is likely to grow at an annualized rate of 37% till 2035. It is worth mentioning that microbiome diagnostics is likely to capture 20% of the total microbiome market share by 2035. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/281/request-sample.html Key Questions Answered  Who are the leading players engaged in the development of microbiome therapeutics?  Which are the key microbiome based drugs being developed across various stages of development?  Which companies are actively involved in conducting clinical trials for microbiome therapeutics and FMTs?  Who are the leading players engaged in the development of microbiome diagnostics and screening / profiling tests?  Which types of partnership models are commonly adopted by industry stakeholders?  Who are the key investors in the field of human microbiome therapeutics and diagnostics?  What are the different initiatives undertaken by big pharma players for the development of human microbiome therapeutics in the recent past?  What is the role of various start-ups engaged in developing human microbiome therapeutics?  Which are the most commonly targeted therapeutic indications for which microbiome therapeutics are being developed?  What are the various steps involved in the manufacturing of microbiome therapeutics?  What are the key considerations for selecting a CMO / CRO for manufacturing of microbiome therapeutics?  What are the various algorithms / tools used to analyze data generated from microbiome research?  How is the current and future opportunity, related to microbiome therapeutics, diagnostics and FMT likely to be distributed across key market segments?  What are the various non-pharma applications of microbiome products? The financial opportunity within the human microbiome therapeutics market has been analyzed across the following segments:  Type of Product  Probiotic Drugs  Other Drugs  Target Indication  Recurrent C. difficile Infection  Necrotizing Enterocolitis  Primary Hyperoxaluria  Graft versus Host Disease  Therapeutic Area  Infectious Diseases  Digestive and GI Disorders  Rare Disorders  Route of Administration  Oral Route  Rectal Route  Type of Formulation  Capsules  Suspensions  Enemas  Key Geographical Regions  North America  Europe  Asia Pacific The financial opportunity within the human microbiome diagnostics and screening / profiling tests market has been analyzed across the following segments:  Target Indication  Irritable Bowel Syndrome  Inflammatory Bowel Disease  Colorectal Cancer  Diabetes Mellitus  Key Geographical Regions  North America  Europe  Asia Pacific The financial opportunity within the fecal microbiota therapies market has been analyzed across the following segments:  Key Geographical Regions  North America  Europe  Asia Pacific The report features inputs from eminent industry stakeholder(s), who were very optimistic concerning the growth of the human microbiome market. It includes detailed transcripts of the discussions held with the senior representatives of the stakeholder firms, including:  Charlie Badham (Senior Manager, Corporate Development, 4D Pharma)  Nicholas Monsul (Co-founder and Chairman, Quorum Innovations)  Alicia Scheffer (Chief Executive Officer, Floragraph)  Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)  Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)  Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)  Assaf Oron (Chief Business Officer, BiomX)  Debbie Pinkston (Former Vice President, Sales and Business Development, List Biological Laboratories)  Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)  Colleen Cutcliffe (Co-founder and Chief Executive Officer, Pendulum Therapeutics)  Nikole Kimes (Co-founder and Chief Executive Officer, Siolta Therapeutics)  James Burges (Ex-Co-founder and Vice President of Innovation, OpenBiome)  Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)  JP Benya (Ex-Vice President, Operations, Assembly Biosciences)  Lee Jones (President and Chief Executive Officer, Rebiotix)  Mark Heiman (Ex-Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics)  Pierre-Alain Bandinelli (Chief Strategy Officer, Da Volterra) The report also includes detailed profiles of the companies (listed below) engaged in developing microbiome therapeutics, diagnostics and screening / profiling test; each profile features an overview of the company, its financial information (if available), details on its product portfolio, recent developments, and an informed future outlook.  4D Pharma  Biosotia Microbiomics  DNA Genotek  Finch Therapeutics  GoodGut  Infant Bacterial Therapeutics  Invivo Healthcare  MaaT Pharma  OxThera  Qu Biologics  Rebiotix  Seres Therapeutics  Servatus  Shoreline Biome For additional details, please visit https://www.rootsanalysis.com/reports/view_document/human-microbiome-market/281.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis [more]
  • jameshebrew
  • The gene therapy market is projected to be worth USD 17.3 billion in 2035, growing at a CAGR of 18%, during the period 2022-2035, claims Roots Analysis Given the potential of gene therapies to permanently cure a diverse array of clinical conditions at the genetic level, the current pipeline is rapidly growing; a number of such therapies are currently being evaluated in late stages of development. London Roots Analysis has announced the addition of “Gene Therapy Market (5th Edition), 2022-2035” report to its list of offerings. Post the emergence of blockbuster gene therapies, such as ZOLGENSMA® (for spinal muscular atrophy type I) and Libmeldy™ (for metachromatic leukodystrophy), this domain has garnered significant interest in the medical community. Moreover, considering the promising trial results of pipeline candidates, notable players have made investments to support product development and commercialization efforts. An analysis of the investments made at various stages, such as seed financing, venture capital financing, IPOs, secondary offerings, debt financing, grants and other equity offerings, by gene therapy companies that are engaged. An elaborate discussion on the various types of viral and non-viral vectors, along with information on design, manufacturing requirements, advantages and limitations of currently available gene delivery vectors. Key Market Insights Over 1,150 gene therapies are currently being developed across different stages Apart from 11 approved products, most of the aforementioned therapies (70%) are in early stages of development (preclinical / discovery), while the rest are being evaluated in clinical trials. It is worth mentioning that more than 40% of the clinical stage candidates target oncological diseases. Further, majority of such therapies (66%) use adenovirus vectors as molecular carriers. More than 250 companies claim to be engaged in the development of gene therapies, globally In the past decade, over 160 companies have been established in this domain. Of the total, 60% of the players are small firms. In addition, majority (62%) of these gene therapy developers are based in North America, primarily in the US. 290+ clinical trials evaluating gene therapies have been registered, worldwide Of the total number of trials registered during the period 2015-2020, close to 10% have already been completed, while 56% are presently recruiting patients. Further, presently, around 55% of the trials are evaluating therapy candidates in phase II studies. USD 8.5+ billion has been invested by both private and public investors, since 2015 The maximum funding amount was raised through secondary offerings (40%), venture capital (28%) and IPOs (16%), during the period 2015-2022. Interestingly, majority (77%) of the funding instances were reported by players based in North America. Over 5,800 patents have been filed / published related to gene therapies, since 2017 Around 90% of the total number of patent applications were related to gene therapies, while the remaining were focused on gene editing-based therapies. Further, majority of the patent assignees were industry players. However, it is worth mentioning that the contribution of non-industry players in the overall patent filing activity has increased considerably (CAGR of 19%), over the past few years. Merger and acquisition activity in this market has grown at a CAGR of 22%, during 2015-2021 It is worth mentioning that, across most of the instances (43%) both the acquirer and the acquired company were based in North America. Moreover, majority of the acquisitions (26%) were focused on providing access to novel platform / technology, followed by acquisitions undertaken for therapeutic area consolidation (24%) and drug class consolidation (24%). The overall market is anticipated to grow at a CAGR of over 18%, during the period 2022-2035 Gene therapies based on gene augmentation currently represent a significant share of the market, and this trend is unlikely to change in the foreseen future, as several such candidates are being evaluated in late stages. North America (primarily the US) is expected to capture 60% of the market share by 2035, in terms of the sales-based revenues. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/268/request-sample.html Key Questions Answered  Who are the key industry players engaged in the development of gene therapies?  How many gene therapy candidates are currently in the development pipeline? Which key disease indications are targeted by such products?  Which types of vectors are most commonly used for effective delivery of gene therapies?  What are the key regulatory requirements for gene therapy approval, across various geographies?  Which commercialization strategies are most commonly adopted by gene therapy developers, across different stages of the development cycle?  What are the different pricing models and reimbursement strategies currently being adopted for gene therapies?  What are the various technology platforms that are either available in the market or are being designed for the development of gene therapies?  Who are the key CMOs / CDMOs engaged in supplying viral / plasmid vectors for gene therapy development?  What are the key value drivers of the merger and acquisition activity in the gene therapy industry?  Who are the key stakeholders that have actively made investments in the gene therapy domain?  Which are the most active trial sites (in terms of number of clinical studies being conducted) for gene therapies?  How is the current and future market opportunity likely to be distributed across key market segments? The financial opportunity within the gene therapy market has been analyzed across the following segments:  Type of Therapy  Gene augmentation  Immunotherapy  Oncolytic viral therapy  Others  Type of Gene Delivery Method Used  Ex vivo  In vivo  Type of Vector Used  Adeno-associated virus  Adenovirus  Herpes simplex virus  Lentivirus  Non-viral vectors  Retrovirus  Others  Target Therapeutic Areas  Cardiovascular diseases  Dermatological diseases  Genetic diseases  Hematological diseases  Infectious diseases  Metabolic diseases  Muscle-related diseases  Oncological diseases  Ophthalmic diseases  Others  Route of Administration  Intraarticular  Intracerebral  Intracoronary  Intradermal  Intralesional  Intramuscular  Intrapleural  Intrathecal  Intratumoral  Intravenous  Intravesical  Intravitreal  Subretinal  Topical  Others  Key Geographical Regions  North America  Europe  Asia-Pacific  Rest of the World The research includes brief profiles of key players (listed below) engaged in the development of gene therapies; each profile features an overview of the therapy, current development status, clinical trials and its results (if available), target indication, route of administration and recent developments (if available).  Abeona Therapeutics  AGTC  AnGes  Biogen  BioMarin Pharmaceutical  bluebird bio  Castle Creek Biosciences  CG Oncology  FerGene  GenSight Biologics  Helixmith  Holostem Terapie Avanzate  Inovio Pharmaceuticals  Kolon TissueGene  Krystal Biotech  Lysogene  Neurophth Therapeutics  Orchard Therapeutics  Pfizer  PTC Therapeutics  REGENXBIO  Sangamo Therapeutics  Spark Therapeutics  VBL Therapeutics For additional details, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • jameshebrew
  • The companion diagnostics development services market, is anticipated to grow at a CAGR of over 10%, till 2035, claims Roots Analysis Given the various challenges associated with co-development of companion diagnostics and drug / therapy, drug developers prefer to rely on third-party service providers that offer customized services and advanced technologies. Roots Analysis has announced the addition of “Companion Diagnostics Development Services Market (2nd Edition), 2022-2035” report to its list of offerings. The growing pipeline of patient-centric targeted therapies has led to a surge in demand for companion diagnostics; these tests are known to improve the success rates of late-stage trials by almost three-fold. The development and approval of these FDA classified high-risk devices requires multidisciplinary expertise and an established network of R&D and production facilities that can be accessed through service providers. Key Market Insights Over 150 companies claim to offer companion diagnostics development services, globally Nearly 60% of the aforementioned players are based in North America, followed by the players located in Europe (30%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 40% of the total service providers. Nearly 15% players claim to act as one-stop shops, offering services, ranging from biomarker discovery and development to manufacturing and commercialization Most of the service providers (127) provide assay development services, followed by companies (124) offering services for biomarker discovery / identification. Further, NGS is the most popular technique, employed by over 100 service providers. Over 90 companies are actively involved in the development of companion diagnostics Nearly 91% of the total tests can detect mutations in a single biomarker. Amongst these, ErbB gene family (HER-2 and EGFR genes), PD-L1 genes, RAS gene family (KRAS and NRAS genes), BRCA gene family (BRCA1 and BRCA2) and BRAF emerged as the key genes which are assessed by majority of the companion diagnostics. Partnership activity in this domain has increased at a CAGR of ~25%, between 2017 and 2021 Mergers and acquisitions, product development agreements and product development and commercialization agreements account for more than 60% of the total number of deals inked during the given time period. It is worth highlighting that nearly 25% of the total number of deals were signed in 2021. Further, the maximum number (177) of partnerships have been inked for companion diagnostics being developed for the treatment of oncological disorders. North America is expected to capture ~60% share in the companion diagnostics development services market by 2035 Owing to the high costs associated with the clinical validation of companion diagnostics, a significant proportion (~46%) of service revenues is generated from this step, in 2035. In terms of analytical technique used, service contracts involving NGS are anticipated to contribute to more than 35% of the total service revenues generated in 2035. Further, close to 90% of the total service revenues, in 2035, are generated from companion diagnostics development projects for cancer indications. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/297/request-sample.html One of the key objectives of the report was to estimate the existing companion diagnostics market size and the potential future growth opportunities for companion diagnostics development service providers. Based on multiple parameters, such as the service cost of various steps involved in companion diagnostics development and manufacturing, and partnerships inked in the last few years for outsourcing of such operations, we have developed informed estimates on the evolution of the market for the time period 2022- 2035. An insightful analysis of companies segregated on the basis of their likelihood to enter into collaborations with companion diagnostics service providers. The chapter features a list of 300+ drug developers sponsoring clinical trials of therapies targeting several disease-specific biomarkers. The players have been shortlisted based on relevant parameters, namely number of biomarker-focused clinical trials sponsored and the time to market their proprietary personalized medicine products. Key Questions Answered  Who are the leading players offering services for the development of companion diagnostics?  Which are the key geographies where companion diagnostics development service providers are located?  Which analytical techniques are used by the service providers engaged companion diagnostics development services market?  Who are the leading companion diagnostics developers?  Which biomarkers are most commonly targeted by the marketed products / investigational programs?  Which partnership models are commonly adopted by stakeholders offering companion diagnostics development services?  Which drug developers are most likely to partner with the service providers to seek their expertise?  What are the key value drivers of the merger and acquisition activity within companion diagnostics development services market?  Which biomarker-focused targeted drugs developed by big pharmaceutical companies are likely to be administered with companion diagnostics?  How is the current and future opportunity likely to be distributed across key market segments? The financial opportunity within the companion diagnostics development services market has been analyzed across the following segments:  Type of Service Offered  Feasibility Studies  Assay Development  Analytical Validation  Clinical Validation  Manufacturing  Type of Technique Used  NGS  PCR  ICH / ISH  Liquid Biopsy  Others  Therapeutic Areas  Oncological  Non-oncological  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World The report also features detailed transcripts of discussions (in reverse chronological order) held with the following experts:  Mike Klein (Chief Executive Officer, Genomenon)  Mark Kiel (Founder and Chief Scientific Officer, Genomenon)  Candace Chapman (Vice President of Marketing, Genomenon)  Anton Iliuk (President and Chief Technology Officer, Tymora Analytical Operations)  Paul Kortschak (Former Senior Vice President, Novodiax)  Pablo Ortiz (Chief Executive officer, OWL Metabolomics)  Lawrence Weiss (Former Chief Scientific Officer, NeoGenomics Laboratories) The research includes detailed profiles of key players (listed below), each profile features an overview of the company, its financial information (if available), drug portfolio, details on recent developments, and an informed future outlook.  Almac Diagnostic Services  BGI Genomics  Biocartis  Cerba Research  Geneuity Clinical Research Services  Interpace Biosciences  Labcorp (formerly known as Covance)  MEDICAL & BIOLOGICAL LABORATORIES (MBL)  MEDx (Suzhou) Translational Medicine (formerly known as QIAGEN (Suzhou) Translational Medicine)  MLM Medical Labs  Novogene  Q2 Solutions  Quest Diagnostics  ResearchDx For additional details, please visit https://www.rootsanalysis.com/reports/view_document/companion-diagnostics-services/297.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Targeted protein degradation market, 2022-2035 2. Cell Therapy Manufacturing Market, 2021-2030 3. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/ [more]
  • MubazGmi
  • Ultrasonic Testing Market Size The Ultrasonic Testing Market is anticipated tog row at a significant CAGR during the forecast period (2021-2028). The factors driving the growth of Ultrasonic Testing Market includes growing application of Ultrasonic Testing in metals, plastics, steel and alloy, rising investments on oil and gas pipelines across the globe, increasing production of electric vehicles and strict regulations imposed by Government. For more info: https://www.snapigram.com/read-blog/67742 [more]
  • MubazGmi
  • Ultrasonic Testing Market Size & Share The Ultrasonic Testing Market is anticipated tog row at a significant CAGR during the forecast period (2021-2028). The factors driving the growth of Ultrasonic Testing Market includes growing application of Ultrasonic Testing in metals, plastics, steel and alloy, rising investments on oil and gas pipelines across the globe, increasing production of electric vehicles and strict regulations imposed by Government. For more info: https://www.nasseej.net/blogs/688/Ultrasonic-Testing-Market-Size-Share-Industry-Report-2021-2028 [more]
  • MubazGmi
  • Ultrasonic Testing Market Size & Share | Industry Report The Ultrasonic Testing Market is anticipated tog row at a significant CAGR during the forecast period (2021-2028). The factors driving the growth of Ultrasonic Testing Market includes growing application of Ultrasonic Testing in metals, plastics, steel and alloy, rising investments on oil and gas pipelines across the globe, increasing production of electric vehicles and strict regulations imposed by Government. For more info: https://joyrulez.com/blogs/159608/Ultrasonic-Testing-Market-Size-Share-Industry-Report-2021-2028 [more]
  • MubazGmi
  • Ultrasonic Testing Market Size & Share | Industry Report, 2028 The Ultrasonic Testing Market is anticipated tog row at a significant CAGR during the forecast period (2021-2028). The factors driving the growth of Ultrasonic Testing Market includes growing application of Ultrasonic Testing in metals, plastics, steel and alloy, rising investments on oil and gas pipelines across the globe, increasing production of electric vehicles and strict regulations imposed by Government. For more info: https://sites.google.com/view/gmiresearch00l/ultrasonic-testing-market-size-share-industry-report-2021-2028 [more]
  • MubazGmi
  • Ultrasonic Testing Market Size & Share | Industry Report, 2021-2028 The Ultrasonic Testing Market is anticipated tog row at a significant CAGR during the forecast period (2021-2028). The factors driving the growth of Ultrasonic Testing Market includes growing application of Ultrasonic Testing in metals, plastics, steel and alloy, rising investments on oil and gas pipelines across the globe, increasing production of electric vehicles and strict regulations imposed by Government. For more info: https://gmiresearch.bcz.com/2022/08/22/ultrasonic-testing-market-size-share-industry-report-2021-2028/ [more]
  • amplizapac
  • Ampliz B2B Database Solutions - Find the right target companies, C - level executives, Segmented target audience, custom B2B database based on firmographics, demographic and geographic. Enhance your sales pipeline with right target audience. Get the list of top 60+ companies in Australia. https://bit.ly/3JrjRU8 #database #b2b #australia #australianbusiness #sales #pipeline #dataintelligence #database #b2bdata #b2baustralia #australiandatabase #australianmanufacturing #australiansmallbusiness
2 3 4 Next Last